Judgment of the General Court of 20 December 2023 – Pharmaselect International and OmniActive Health Technologies v EUIPO – OmniActive Health Technologies and Pharmaselect International (LUTAMAX)
(Joined Cases T-221/22 and T-242/22) 1
(EU trade mark – Revocation proceedings – EU word mark LUTAMAX – Genuine use of the mark – Article 51(1)(a) of Regulation (EC) No 207/2009 (now Article 58(1)(a) of Regulation (EU) 2017/1001) – Obligation to state reasons – Article 94(1) of Regulation 2017/1001)
Language of the case: English
Parties
Applicant in Case T-221/22: Pharmaselect International Beteiligungs GmbH (Vienna, Austria) (represented by: S. Jackermeier, D. Wiedemann and M. Ringer, lawyers)
Applicant in Case T-242/22: OmniActive Health Technologies Ltd (Mumbai, India) (represented by: M. Hawkins, T. Dolde and C. Zimmer, lawyers)
Defendant: European Union Intellectual Property Office (represented by: D. Stoyanova-Valchanova and D. Gája, acting as Agents)
Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court in Case T-221/22: OmniActive Health Technologies (Mumbai) (represented by: M. Hawkins, T. Dolde and C. Zimmer, lawyers)
Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court in Case T-242/22: Pharmaselect International Beteiligungs (Vienna) (represented by: S. Jackermeier, D. Wiedemann and M. Ringer, lawyers)
Re:
By their actions under Article 263 TFEU, the applicants seek the annulment of the decision of the First Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 24 February 2022 (Joined Cases R 524/2021-1 and R 649/2021-1).
Operative part of the judgment
The Court:
Annuls point 2 of the operative part of the decision of the First Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 24 February 2022 (Joined Cases R 524/2021-1 and R 649/2021-1);
Dismisses the action in Case T-221/22 as to the remainder;
Dismisses the action in Case T-242/22;
Orders Pharmaselect International Beteiligungs GmbH, EUIPO and OmniActive Health Technologies Ltd to bear their own respective costs in Case T-221/22;
Orders, in Case T-242/22, OmniActive Health Technologies Ltd to bear its own costs and to pay the costs incurred by EUIPO and by Pharmaselect International Beteiligungs GmbH.
____________
1 OJ C 237, 20.6.2022.